After signing up, you'll start to receive regular news updates from us.
Therapure Biopharma Announces Collaboration with BioVectra
Complete the form below to unlock access to ALL audio articles.
BioVectra Inc. and Therapure BioPharma Inc. have agreed to partner in the development of a PEGylated biologic drug target used for cancer treatments, with a goal of advancing the project to a regulatory filing stage, suitable for a marketing partner to add to its portfolio of biologic products.
Over the past five years, BioVectra has been developing proprietary technologies for PEGylation as a mechanism for drug delivery. The partnership with Therapure builds upon BioVectra's expertise in the production of modified biologic molecules using a proprietary MPEG technology.
Therapure, from its 130,000 sq. ft facilities in Mississauga, Ontario, adds proprietary purification techniques and impressive formulation, fill, and finish expertise in biologics handling.
"We are very excited about working with BioVectra," said Thomas Wellner, President and CEO of Therapure Biopharma. "They bring significant expertise in active pharmaceutical ingredient development and a high degree of competence and commitment to our partnership."
"Our current program for drug development depends on finding the right partners," said Dale Zajicek, COO and VP of Business Development for BioVectra. "We know we have made a good choice in Therapure Biopharma and we look forward to working together to further the development and commercialization of this product."
